Government entities threw CV specialists for a loop in 2025 with changes that will inevitably affect patient care.

New evidence for treatment of pulmonary embolism, asymptomatic carotid stenosis, and CLTI led the way in 2025.

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

Health-related social needs in HF, removing age from frailty scores, CIED concerns about smartwatches, and more.

As research continues into how AI will impact practice, there are open questions about medical training, regulation, and more ...

In 2025, cardiology delved deeper into sex-specific risk factors and how to leverage them in prevention, Stacey Rosen says.

The Volt pulsed-field ablation (PFA) system (Abbott) has been approved by the US Food and Drug Administration for the treatment of patients with atrial fibrillation (AF), according to a Monday ...

By improving BP control and treatment adherence, use of fixed-dose combination therapies is expected to drive down CV events ...

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

Gaxiola López shaped the field of interventional cardiology, with colleagues saying he’ll be remembered as a “visionary.” ...

The drug was as good as a proven GLP-1, giving doctors another potent option for patients with type 2 diabetes and ...